HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc06-2001v1 30/6/1480    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rosenstock, J. Search for Related Content PubMed PubMed Citation Articles by Rosenstock, J. Social Bookmarking                What's this?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled-Release in the Treatment of Obese, Type 2 Diabetic Patients

¹Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
²Baylor Hospital, Dallas, Texas, USA
³Duke University School of Medicine, Durham, North Carolina, USA
⁴Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey, USA

juliorosenstock{at}dallasdiabetes.com

ABSTRACT

Objective:: This is a randomized, placebo-controlled study of the weight loss efficacy and safety of a controlled-release (CR) formulation of topiramate in overweight and obese patients with type 2 diabetes, treated with diet and exercise alone, or in combination with metformin.

Research Design and Methods:: Patients with type 2 diabetes, BMI 27, with HbA_1c >6.5% and <11.0%, treated with diet and exercise alone or in combination with metformin monotherapy were enrolled. Patients were randomized to placebo or topiramate CR titrated up to 175 mg/d. Treatment consisted of a 7-week titration phase followed by a 9-week maintenance phase.

Results:: A total of 111 subjects were randomized and analyzed. By the end of week 16, patients in the placebo and topiramate groups lost 2.5 kg and 6.0 kg, which represented 2.3% and 5.8%, respectively, of their baseline body weight (P<0.001 vs placebo). HbA_1c improved from a baseline of 7.4% in the placebo and 7.6% in the topiramate groups to 7.1% and 6.7% respectively, representing a 0.4%, and 0.9% reduction from baseline (P<0.001 vs. placebo). Topiramate also significantly reduced blood pressure and urinary albumin excretion. Adverse events were predominantly neuropsychiatric, or central and peripheral nervous system-related.

Conclusion:: Topiramate CR treatment produced significant weight loss and meaningful improvements in HbA_1c and blood pressure in obese patients with type 2 diabetes mellitus treated with diet and exercise or in combination with metformin. However, the CNS and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes.

The study has been registered at www.ClinicalTrials.gov, identifier NCT00231647.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?